McShane, LM, Irwin, N, O'Flynn, D, Franklin, ZJ, Hewage, CM and O'Harte, FPM
(2016)
Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
JOURNAL OF ENDOCRINOLOGY, 229 (3).
pp. 319-330.
Text
GRA paper 2.pdf - Unspecified Download (2MB) |
Abstract
Ablation of glucagon receptor signaling represents a potential treatment option for type 2 diabetes (T2DM). Additionally, activation of glucose-dependent insulinotropic polypeptide (GIP) receptor signaling also holds therapeutic promise for T2DM. Therefore, this study examined both independent and combined metabolic actions of desHis(1)Pro(4)Glu(9)(Lys(12)PAL)-glucagon (glucagon receptor antagonist) and d-Ala(2)GIP (GIP receptor agonist) in diet-induced obese mice. Glucagon receptor binding has been linked to alpha-helical structure and desHis(1)Pro(4)Glu(9)(Lys(12)PAL)-glucagon displayed enhanced alpha-helical content compared with native glucagon. In clonal pancreatic BRIN-BD11 beta-cells, desHis(1)Pro(4)Glu(9)(Lys(12)PAL)-glucagon was devoid of any insulinotropic or cAMP-generating actions, and did not impede d-Ala(2)GIP-mediated (P<0.01 to P<0.001) effects on insulin and cAMP production. Twice-daily injection of desHis(1)Pro(4)Glu(9)(Lys(12)PAL)-glucagon or d-Ala(2)GIP alone, and in combination, in high-fat-fed mice failed to affect body weight or energy intake. Circulating blood glucose levels were significantly (P<0.05 to P<0.01) decreased by all treatments regimens, with plasma and pancreatic insulin elevated (P<0.05 to P<0.001) in all mice receiving d-Ala(2)GIP. Interestingly, plasma glucagon concentrations were decreased (P<0.05) by sustained glucagon inhibition (day 28), but increased (P<0.05) by d-Ala(2)GIP therapy, with a combined treatment resulting in glucagon concentration similar to saline controls. All treatments improved (P<0.01) intraperitoneal and oral glucose tolerance, and peripheral insulin sensitivity. d-Ala(2)GIP-treated mice showed increased glucose-induced insulin secretion in response to intraperitoneal and oral glucose. Metabolic rate and ambulatory locomotor activity were increased (P<0.05 to P<0.001) in all desHis(1)Pro(4)Glu(9)(Lys(12)PAL)-glucagon-treated mice. These studies highlight the potential of glucagon receptor inhibition alone, and in combination with GIP receptor activation, for T2DM treatment.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | glucagon, glucose-dependent insulinotropic polypeptide (GIP), glucose homeostasis, insulin secretion, insulin sensitivity, glucagon receptor antagonist, GIP receptor agonist, diet-induced obese diabetic mice |
Depositing User: | Symplectic Admin |
Date Deposited: | 18 May 2016 09:18 |
Last Modified: | 19 Jan 2023 07:36 |
DOI: | 10.1530/JOE-15-0463 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3001271 |